Edwards Lifesciences (EW) provided guidance Wednesday for 2025.
The the medical technology company said it expects full-year adjusted earnings per share of $2.40 to $2.50 on sales of $5.6 billion to $6.0 billion.
Analysts polled by Factset expect non-GAAP EPS of $2.45 on sales of $5.91 billion.